Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3301 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Forest and Mylan amend Bystolica agreement

Under the terms of this amendment, Forest Laboratories Holdings (Ireland) will make a one-time cash payment of $370 million to Mylan. Forest will continue to pay Mylan its

FDA to review Ovation’s Sabril NDA

The FDA assigned a priority NDA review for Sabril for the treatment of infantile spasms (IS), and will review the submission for refractory complex partial seizures (CPS) in